186 related articles for article (PubMed ID: 12454761)
1. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.
Addo S; Yates RA; Laight A
Br J Cancer; 2002 Dec; 87(12):1354-9. PubMed ID: 12454761
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant: pharmacokinetics and pharmacology.
Robertson JF; Harrison M
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S7-10. PubMed ID: 15094758
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
Robertson JF; Erikstein B; Osborne KC; Pippen J; Come SE; Parker LM; Gertler S; Harrison MP; Clarke DA
Clin Pharmacokinet; 2004; 43(8):529-38. PubMed ID: 15170367
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I; Robertson JF
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Croxtall JD; McKeage K
Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
[TBL] [Abstract][Full Text] [Related]
7. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
8. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.
Piccart M; Parker LM; Pritchard KI
Ann Oncol; 2003 Jul; 14(7):1017-25. PubMed ID: 12853342
[TBL] [Abstract][Full Text] [Related]
9. A new estrogen receptor antagonist--an overview of available data.
Jones SE
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant.
Cheung KL; Robertson JF
Expert Opin Investig Drugs; 2002 Feb; 11(2):303-8. PubMed ID: 11829719
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Chia S; Gradishar W
Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer.
Robertson JF; Odling-Smee W; Holcombe C; Kohlhardt SR; Harrison MP
Clin Ther; 2003 May; 25(5):1440-52. PubMed ID: 12867220
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of fulvestrant ("Faslodex").
Howell A; Abram P
Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.
Nuttall ME; Pendrak I; Emery JG; Nadeau DP; Fisher PW; Nicholson TA; Zhu Y; Suva LJ; Kingsbury WD; Gowen M
Cancer Chemother Pharmacol; 2001 May; 47(5):437-43. PubMed ID: 11391860
[TBL] [Abstract][Full Text] [Related]
17. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.
Zhang Q; Shao Z; Shen K; Li L; Feng J; Tong Z; Gu K; Wang X; Xu B; Sun G; Chen H; Rukazenkov Y; Jiang Z
Oncotarget; 2016 Aug; 7(35):57301-57309. PubMed ID: 27359058
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
Johnston S
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S15-8. PubMed ID: 15094760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
